Status:

COMPLETED

Psoriasis Inflammation and Systemic Co Morbidities

Lead Sponsor:

Rockefeller University

Collaborating Sponsors:

Weill Medical College of Cornell University

Conditions:

Psoriasis

Eligibility:

All Genders

18-75 years

Phase:

NA

Brief Summary

Psoriasis is a chronic relapsing prevalent inflammatory disease affecting 2-4% of the world's population. Severe psoriasis is a disabling disease affecting the physical and emotional well being of pat...

Detailed Description

Psoriasis is the most prevalent immune-mediated skin disease affecting 2-4% of the world's population. Severe psoriasis is a disabling disease affecting the physical and emotional well being of patien...

Eligibility Criteria

Inclusion

  • Age ≥ 18years
  • Psoriasis affecting Body Surface Area (BSA) ≥ 10% after washout
  • No systemic anti psoriatic therapy ≤ 30days
  • Plaque type Psoriasis

Exclusion

  • Overt diabetes (\> 135 mg/dL fasting blood glucose on two (2) separate occasions
  • Hypertension as defined as a systolic BP \> 140 \&/or a diastolic pressure \> 90. -Cannot be on more then one (1) antihypertensive medication.
  • Currently have any known malignancy or have a history of malignancy in the 5 past years excluding basal cell carcinoma.
  • S/P Cardiovascular event such as Myocardial infarction, any open heart surgery, stroke or other vascular occlusive event.
  • Known allergy to etanercept
  • HIV positive
  • HBV positive
  • HbA1C \>7
  • Current use of hypoglycemic medication
  • Current use of any anticoagulants
  • Current use of any anti-inflammatory medications (except inhaled steroids)
  • Females of childbearing age who are pregnant or breast-feeding or not using a contraceptive.
  • NYHA Class III and Class IV heart failure
  • Positive PPD
  • History, physical, or laboratory findings suggestive of any other medical or psychological condition that would, in the opinion of the Principal Investigator, make the candidate ineligible for the study.

Key Trial Info

Start Date :

July 13 2010

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

September 9 2013

Estimated Enrollment :

29 Patients enrolled

Trial Details

Trial ID

NCT01170715

Start Date

July 13 2010

End Date

September 9 2013

Last Update

February 8 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

The Rockefeller University

New York, New York, United States, 10065

Psoriasis Inflammation and Systemic Co Morbidities | DecenTrialz